ID   MFH-ino
AC   CVCL_1407
SY   MFH-INO
DR   CLO; CLO_0050084
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472224
DR   CCLE; MFHINO_SOFT_TISSUE
DR   Cell_Model_Passport; SIDM00299
DR   ChEMBL-Cells; CHEMBL3308269
DR   ChEMBL-Targets; CHEMBL2366262
DR   Cosmic; 925343
DR   Cosmic-CLP; 925343
DR   DepMap; ACH-002271
DR   GDSC; 925343
DR   GEO; GSM1670101
DR   IARC_TP53; 27563
DR   LINCS_LDP; LCL-1753
DR   RCB; RCB0749
DR   Wikidata; Q54905391
RX   PubMed=1653597;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: 43 hours (at 41th passage), 32 hours (at 78th passage) (PubMed=1653597).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Has no TP53 mutation (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=75.44%; East Asian, South=24.26%; South Asian=0.29%; European, North=0%; European, South=0% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11
ST   D5S818: 12
ST   D7S820: 9,11
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 16,19
DI   NCIt; C4247; Undifferentiated pleomorphic sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 23
//
RX   PubMed=1653597;
RA   Takahashi K., Sato K.;
RT   "Establishment and characterization of a human neoplastic cell line
RT   (MFH-ino) derived from malignant fibrous histiocytoma of maxilla.";
RL   Hum. Cell 4:51-57(1991).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//